MIMOSA Diagnostics Inc.

MIMOSA Diagnostics is a Canadian medical technology company specializing in portable near-infrared multispectral and hyperspectral imaging for non-invasive tissue health assessment at the point-of-care. The flagship MIMOSA Pro device is a pocket-sized imaging tool designed for healthcare professionals to assess tissue oximetry, temperature, wound measurements, and other biomarkers in real-time. The device integrates with a secure cloud-based web portal for remote image review, patient monitoring, and clinical collaboration. Primary clinical applications include wound care (diabetic foot ulcers, chronic wounds), peripheral vascular disease assessment, post-operative tissue viability evaluation, burn depth assessment, and pediatric wound management. MIMOSA Pro addresses accessibility gaps in healthcare, particularly for patients in remote areas and those with diverse skin tones, enabling early intervention to prevent limb loss and improve outcomes. The platform streamlines clinical workflows by allowing any trained healthcare professional to capture images on-site (clinic, hospital, or home-care), with clinicians reviewing results remotely and in real-time. Founded by Dr. Karen Cross, a plastic surgeon and wound healing expert, the company has secured $6.1 million in funding and is commercializing in the U.S. market.